Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $46.57 USD
Change Today -2.16 / -4.43%
Volume 140.0K
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (FMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $54.28
52 Week Low
10/1/14 - $18.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

foundation medicine inc (FMI) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (FMI) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The company provides clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. It also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, foster relationships throughout the oncology community, and develop new clinical and technology products. In addition, the company has a strategic collaboration agreement with WuXi PharmaTech Inc. to provide genomic profiles to biopharmaceutical companies conducting clinical trials; and F. Hoffmann-La Roche Ltd. to develop and commercialize molecular information and genomic analysis products for the treatment of cancer patients. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

293 Employees
Last Reported Date: 03/13/15
Founded in 2009

foundation medicine inc (FMI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $403.9K
President and Chief Operating Officer
Total Annual Compensation: $336.8K
Chief Medical Officer
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

foundation medicine inc (FMI) Key Developments

Foundation Medicine, Inc. Amends Certificate of Incorporation

Foundation Medicine, Inc. announced the closing of its strategic transaction with Roche Holdings, Inc. This transaction included the purchase by Roche of approximately 15.6 million shares of common stock by means of a tender offer from Foundation Medicine stockholders at a price of $50 per share. Concurrently, Roche also purchased an additional 5 million newly issued shares directly from the company at the same price per share for gross proceeds to Foundation Medicine of $250 million. In connection with the completion of the Investment, Foundation Medicine, Inc.'s Certificate of Incorporation was amended and restated to provide for, among other things, the declassification of the Board and the waiver of the corporate opportunity doctrine with respect to Roche and its affiliates. The amendments to the Certificate of Incorporation were approved by the company's stockholders at a special meeting of stockholders held on April 2, 2015.

Foundation Medicine, Inc. Appoints KPMG LLP as New Independent Public Accounting Firm Replacing Ernst & Young LLP

On April 6, 2015, Ernst & Young LLP resigned as Foundation Medicine, Inc.'s independent registered public accounting firm, and Ernst & Young's resignation was accepted and approved by the audit committee of the Board of Directors of the company. The audit committee of the Board approved KPMG LLP as the company's new independent public accounting firm, subject to KPMG completing its standard client engagement procedures and accepting the engagement, to audit the company's consolidated financial statements for the fiscal year ended December 31, 2015.

Foundation Medicine announces management changes

Foundation Medicine, Inc., has appointed Matt Franklin as senior vice president, global marketing. Michael Pellini, M.D., continues as CEO with executive team leadership responsibility and increasing focus on strategic initiatives, corporate vision and long-term growth. Dr. Pellini will also continue as a member of Foundation Medicine's Board of Directors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMI:US $46.57 USD -2.16

FMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.07 USD -0.05
Genomic Health Inc $30.59 USD -0.29
NeoGenomics Inc $4.75 USD -0.11
Response Genetics Inc $0.29 USD -0.002
Sequenom Inc $4.52 USD -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation FMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.5x
Price/Book 16.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at